Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 107

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 107
---
, as of April
1, 2025, assuming exercise of the warrants held by the selling shareholders on that date, without regard to any limitations on conversions
or exercises. The third column lists the maximum number of Ordinary Shares represented by Depositary Shares being offered in this prospectus
by the selling shareholders. The fourth and fifth columns list the amount of Ordinary Shares represented by Depositary Shares owned after
the offering, by number of Ordinary Shares represented by Depositary Shares and percentage of outstanding Ordinary Shares, assuming in
both cases the sale of all of the Ordinary Shares represented by Depositary Shares offered by the selling shareholders pursuant to this
prospectus, and without regard to any limitations on conversions or exercises.

In accordance with the terms
of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale of the sum of (i) the number
of Ordinary Shares issued to the selling shareholders at the Closing and the number of Ordinary Shares issued to the selling shareholders
upon the exercise of the warrants issued at the Closing and (ii) the maximum number of Ordinary Shares upon exercise of the related warrants,
determined as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date this registration
statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and
all subject to adjustment as provided in the registration right agreement, without regard to any limitations on the exercise of the warrants.

Under the terms of the warrants,
a selling shareholder may not exercise the warrants to the extent such exercise would cause such selling shareholder, together with its
affiliates and attribution parties, to beneficially own a number of Ordinary Shares which would exceed 4.99% or 9.99%, as applicable,
of our then outstanding Ordinary Shares following such exercise, excluding for purposes of such determination Ordinary Shares issuable
upon exercise of such warrants which have not been exercised. The beneficial ownership limitation may be increased or decreased, provided
that in no event shall it exceed 9.99%, upon notice to us, provided that any increase in the beneficial ownership limitation shall not
be effective until 61 days following the receipt of such notice by us. The number of shares in the table below does not reflect this limitation.
See “Plan of Distribution.” The selling shareholders may sell all, some or none of their Ordinary Shares in this offering.
See “Plan of Distribution.”

| Name of Selling Shareholder                    |     | Number of Ordinary 
 Shares Owned Prior 
 to